Johnson & Johnson (JNJ) PT Raised to $147.00 at Raymond James

Johnson & Johnson (NYSE:JNJ) had its price objective raised by analysts at Raymond James from $145.00 to $147.00 in a research report issued to clients and investors on Wednesday, BenzingaRatingsTable reports. The brokerage currently has an “outperform” rating on the stock. Raymond James’ target price indicates a potential upside of 6.61% from the stock’s previous close.

Several other equities research analysts have also recently commented on JNJ. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target for the company in a report on Wednesday, March 27th. Citigroup increased their price target on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Barclays reaffirmed an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Finally, Morgan Stanley set a $140.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and a consensus target price of $144.67.

Shares of NYSE JNJ traded down $0.13 during midday trading on Wednesday, hitting $137.89. The stock had a trading volume of 1,734,327 shares, compared to its average volume of 5,437,931. The company has a market cap of $370.29 billion, a PE ratio of 16.86, a price-to-earnings-growth ratio of 2.21 and a beta of 0.68. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the business posted $2.06 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 8.58 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of JNJ. Evolution Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $40,000. Crewe Advisors LLC boosted its holdings in Johnson & Johnson by 75.0% in the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock valued at $45,000 after purchasing an additional 150 shares during the period. Horan Securities Inc. boosted its holdings in Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after purchasing an additional 241 shares during the period. First Bank & Trust boosted its holdings in Johnson & Johnson by 30.4% in the first quarter. First Bank & Trust now owns 399 shares of the company’s stock valued at $56,000 after purchasing an additional 93 shares during the period. Finally, Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the first quarter valued at $58,000. 67.32% of the stock is owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: How Buying a Call Option Works

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit